Literature DB >> 12672960

T cell leukemia I oncogene expression depends on the presence of Epstein-Barr virus in the virus-carrying Burkitt lymphoma lines.

Csaba Kiss1, Jun Nishikawa, Kenzo Takada, Pankaj Trivedi, George Klein, Laszlo Szekely.   

Abstract

We used a modified subtractive suppression hybridization to identify cellular genes that show altered expression in Burkitt lymphomas (BLs) in the presence of Epstein-Barr virus (EBV). Comparison of the gene expression patterns of an EBV-negative clone of the originally EBV-positive BL line Akata, with its Neo(R)-EBV derivative, revealed a significant difference in the expression of the T cell leukemia 1 oncogene (TCL-1). Subsequent expression studies showed that the original EBV-positive Akata line and the EBV-reconstituted derivative expressed high levels of TCL-1, whereas the EBV-negative variant showed only a low level of expression. Two other independently established EBV-positive BLs (Mutu and OMA) that have also thrown off EBV showed a similar decrease in TCL-1 expression after virus loss. Reinfection with Neo(R)-EBV restored the TCL-1 expression levels in the EBV loss variants to as high a level as the originally EBV-positive lines. High-resolution immunostaining showed that TCL-1 was localized in both the cytoplasm and the nucleus. Our findings suggest that high expression of TCL-1 is necessary for the development of the BL phenotype. In view of the fact that germinal center B cells, regarded as the progenitors of BL, do not express TCL-1, we suggest that constitutive expression of this oncogene occurs by genetic or epigenetic changes in the EBV-negative BLs. In the originally EBV-positive BLs, the ability of the virus to switch on TCL-1 expression would obviate this need.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12672960      PMCID: PMC153638          DOI: 10.1073/pnas.0730710100

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  33 in total

1.  Clonal propagation of Epstein-Barr virus (EBV) recombinants in EBV-negative Akata cells.

Authors:  N Shimizu; H Yoshiyama; K Takada
Journal:  J Virol       Date:  1996-10       Impact factor: 5.103

2.  Real-time DNA sequencing using detection of pyrophosphate release.

Authors:  M Ronaghi; S Karamohamed; B Pettersson; M Uhlén; P Nyrén
Journal:  Anal Biochem       Date:  1996-11-01       Impact factor: 3.365

3.  TCL1 is activated by chromosomal rearrangement or by hypomethylation.

Authors:  M R Yuille; A Condie; E M Stone; J Wilsher; P S Bradshaw; L Brooks; D Catovsky
Journal:  Genes Chromosomes Cancer       Date:  2001-04       Impact factor: 5.006

4.  Parallel existence of Epstein-Barr virus (EBV) positive and negative cells in a sporadic case of Burkitt lymphoma.

Authors:  P Trivedi; Q J Zhang; F Chen; J Minarovits; M Ekman; P Biberfeld; G Klein; G Winberg
Journal:  Oncogene       Date:  1995-08-03       Impact factor: 9.867

5.  Chromosome walking on the TCL1 locus involved in T-cell neoplasia.

Authors:  L Virgilio; M Isobe; M G Narducci; P Carotenuto; B Camerini; N Kurosawa; C M Croce; G Russo
Journal:  Proc Natl Acad Sci U S A       Date:  1993-10-15       Impact factor: 11.205

6.  Identification of the TCL1 gene involved in T-cell malignancies.

Authors:  L Virgilio; M G Narducci; M Isobe; L G Billips; M D Cooper; C M Croce; G Russo
Journal:  Proc Natl Acad Sci U S A       Date:  1994-12-20       Impact factor: 11.205

7.  Isolation of Epstein-Barr virus (EBV)-negative cell clones from the EBV-positive Burkitt's lymphoma (BL) line Akata: malignant phenotypes of BL cells are dependent on EBV.

Authors:  N Shimizu; A Tanabe-Tochikura; Y Kuroiwa; K Takada
Journal:  J Virol       Date:  1994-09       Impact factor: 5.103

8.  Characterization of a newly established human Burkitt's lymphoma cell line, OMA-BL-1.

Authors:  S S Joshi; J M DeBoer; S J Strandjord; S J Pirruccello; W G Sanger; D D Weisenburger; J G Sharp
Journal:  Int J Cancer       Date:  1991-03-12       Impact factor: 7.396

9.  Expression of either the TCL1 oncogene, or transcripts from its homologue MTCP1/c6.1B, in leukaemic and non-leukaemic T cells from ataxia telangiectasia patients.

Authors:  J Thick; J A Metcalfe; Y F Mak; D Beatty; M Minegishi; M J Dyer; G Lucas; A M Taylor
Journal:  Oncogene       Date:  1996-01-18       Impact factor: 9.867

10.  TCL1 oncogene activation in preleukemic T cells from a case of ataxia-telangiectasia.

Authors:  M G Narducci; L Virgilio; M Isobe; A Stoppacciaro; R Elli; M Fiorilli; M Carbonari; A Antonelli; L Chessa; C M Croce; G Russo
Journal:  Blood       Date:  1995-09-15       Impact factor: 22.113

View more
  10 in total

1.  Parvovirus nonstructural proteins induce an epigenetic modification through histone acetylation in host genes and revert tumor malignancy to benignancy.

Authors:  Hiroyoshi Iseki; Rie Shimizukawa; Fumihiro Sugiyama; Satoshi Kunita; Atsushi Iwama; Masafumi Onodera; Hiromitsu Nakauchi; Ken-ichi Yagami
Journal:  J Virol       Date:  2005-07       Impact factor: 5.103

2.  EBNA2 interferes with the germinal center phenotype by downregulating BCL6 and TCL1 in non-Hodgkin's lymphoma cells.

Authors:  Francesco Boccellato; Eleni Anastasiadou; Paola Rosato; Bettina Kempkes; Luigi Frati; Alberto Faggioni; Pankaj Trivedi
Journal:  J Virol       Date:  2006-12-06       Impact factor: 5.103

3.  Cellular target genes of Epstein-Barr virus nuclear antigen 2.

Authors:  Sabine Maier; Gabriele Staffler; Andrea Hartmann; Julia Höck; Karen Henning; Kristina Grabusic; Reinhard Mailhammer; Reinhard Hoffmann; Matthias Wilmanns; Roland Lang; Jörg Mages; Bettina Kempkes
Journal:  J Virol       Date:  2006-10       Impact factor: 5.103

4.  EBNA-3B- and EBNA-3C-regulated cellular genes in Epstein-Barr virus-immortalized lymphoblastoid cell lines.

Authors:  Adrienne Chen; Bo Zhao; Elliott Kieff; Jon C Aster; Fred Wang
Journal:  J Virol       Date:  2006-10       Impact factor: 5.103

5.  TORC2 regulates germinal center repression of the TCL1 oncoprotein to promote B cell development and inhibit transformation.

Authors:  Ali I Kuraishy; Samuel W French; Mara Sherman; Marco Herling; Dan Jones; Randolph Wall; Michael A Teitell
Journal:  Proc Natl Acad Sci U S A       Date:  2007-06-04       Impact factor: 11.205

6.  Synergy of Myc, cell cycle regulators and the Akt pathway in the development of aggressive B-cell lymphoma in a mouse model.

Authors:  K Arita; S Tsuzuki; K Ohshima; T Sugiyama; M Seto
Journal:  Leukemia       Date:  2014-07-18       Impact factor: 11.528

7.  Editing of Epstein-Barr virus-encoded BART6 microRNAs controls their dicer targeting and consequently affects viral latency.

Authors:  Hisashi Iizasa; Bjorn-Erik Wulff; Nageswara R Alla; Manolis Maragkakis; Molly Megraw; Artemis Hatzigeorgiou; Dai Iwakiri; Kenzo Takada; Andreas Wiedmer; Louise Showe; Paul Lieberman; Kazuko Nishikura
Journal:  J Biol Chem       Date:  2010-08-17       Impact factor: 5.157

8.  c-Myc and Rel/NF-kappaB are the two master transcriptional systems activated in the latency III program of Epstein-Barr virus-immortalized B cells.

Authors:  Nathalie Faumont; Stéphanie Durand-Panteix; Martin Schlee; Sebastian Grömminger; Marino Schuhmacher; Michael Hölzel; Gerhard Laux; Reinhard Mailhammer; Andreas Rosenwald; Louis M Staudt; Georg W Bornkamm; Jean Feuillard
Journal:  J Virol       Date:  2009-03-04       Impact factor: 5.103

9.  Nodal diffuse large B-cell lymphomas in children and adolescents: immunohistochemical expression patterns and c-MYC translocation in relation to clinical outcome.

Authors:  Gabriela Gualco; Lawrence M Weiss; William J Harrington; Carlos E Bacchi
Journal:  Am J Surg Pathol       Date:  2009-12       Impact factor: 6.394

10.  T-Cell Leukemia/Lymphoma 1 (TCL1): An Oncogene Regulating Multiple Signaling Pathways.

Authors:  Francesco Paduano; Eugenio Gaudio; Afua A Mensah; Sandra Pinton; Francesco Bertoni; Francesco Trapasso
Journal:  Front Oncol       Date:  2018-08-13       Impact factor: 6.244

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.